These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26159181)
1. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Üstündağ-Okur N; Gökçe EH; Bozbıyık Dİ; Eğrilmez S; Ertan G; Özer Ö Expert Opin Drug Deliv; 2015; 12(11):1791-807. PubMed ID: 26159181 [TBL] [Abstract][Full Text] [Related]
2. Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. Ustündağ-Okur N; Gökçe EH; Bozbıyık Dİ; Eğrilmez S; Ozer O; Ertan G Eur J Pharm Sci; 2014 Oct; 63():204-15. PubMed ID: 25111119 [TBL] [Abstract][Full Text] [Related]
3. Transport mechanism of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan decorated coumarin-6 loaded nanostructured lipid carriers across the rabbit ocular. Li J; Tan G; Cheng B; Liu D; Pan W Eur J Pharm Biopharm; 2017 Nov; 120():89-97. PubMed ID: 28867370 [TBL] [Abstract][Full Text] [Related]
4. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. Fu T; Yi J; Lv S; Zhang B J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model. Ubani-Ukoma U; Gibson D; Schultz G; Silva BO; Chauhan A Int J Pharm; 2019 Jun; 565():499-508. PubMed ID: 31085257 [TBL] [Abstract][Full Text] [Related]
6. Development, Optimization, and In Vitro/In Vivo Characterization of Enhanced Lipid Nanoparticles for Ocular Delivery of Ofloxacin: the Influence of Pegylation and Chitosan Coating. Eid HM; Elkomy MH; El Menshawe SF; Salem HF AAPS PharmSciTech; 2019 May; 20(5):183. PubMed ID: 31054011 [TBL] [Abstract][Full Text] [Related]
8. Development of besifloxacin HCl loaded nanofibrous ocular inserts for the treatment of bacterial keratitis: In vitro, ex vivo and in vivo evaluation. Polat HK; Bozdağ Pehlivan S; Özkul C; Çalamak S; Öztürk N; Aytekin E; Fırat A; Ulubayram K; Kocabeyoğlu S; İrkeç M; Çalış S Int J Pharm; 2020 Jul; 585():119552. PubMed ID: 32569814 [TBL] [Abstract][Full Text] [Related]
9. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide). Di Colo G; Zambito Y; Burgalassi S; Serafini A; Saettone MF Int J Pharm; 2002 Nov; 248(1-2):115-22. PubMed ID: 12429465 [TBL] [Abstract][Full Text] [Related]
10. Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Di Colo G; Burgalassi S; Chetoni P; Fiaschi MP; Zambito Y; Saettone MF Int J Pharm; 2001 Mar; 215(1-2):101-11. PubMed ID: 11250096 [TBL] [Abstract][Full Text] [Related]
11. Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits. Fukaya Y; Kurita A; Tsuruga H; Naito A; Nakaya S; Sato M; Kamata Y; Hirata H; Kambara Y; Kurasawa N; Wada T; Toyoda Y; Shirasawa E; Ohashi Y J Ocul Pharmacol Ther; 2006 Aug; 22(4):258-66. PubMed ID: 16910867 [TBL] [Abstract][Full Text] [Related]
12. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. Mannis MJ Trans Am Ophthalmol Soc; 2002; 100():243-71. PubMed ID: 12545697 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. Moreau JM; Green LC; Engel LS; Hill JM; O'Callaghan RJ Curr Eye Res; 1998 Aug; 17(8):808-12. PubMed ID: 9723996 [TBL] [Abstract][Full Text] [Related]
14. Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide). Di Colo G; Burgalassi S; Chetoni P; Fiaschi MP; Zambito Y; Saettone MF Int J Pharm; 2001 Jun; 220(1-2):169-77. PubMed ID: 11376979 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. Oguz H; Ozbilge H; Oguz E; Gurkan T Curr Eye Res; 2005 Mar; 30(3):155-61. PubMed ID: 15804740 [TBL] [Abstract][Full Text] [Related]
16. Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system. Sayed EG; Hussein AK; Khaled KA; Ahmed OA Drug Des Devel Ther; 2015; 9():1427-35. PubMed ID: 25792803 [TBL] [Abstract][Full Text] [Related]
17. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. Liu R; Liu Z; Zhang C; Zhang B J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401 [TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of ocular drug delivery system. Gorle AP; Gattani SG Pharm Dev Technol; 2010; 15(1):46-52. PubMed ID: 19552545 [TBL] [Abstract][Full Text] [Related]
20. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Li X; Nie SF; Kong J; Li N; Ju CY; Pan WS Int J Pharm; 2008 Nov; 363(1-2):177-82. PubMed ID: 18706987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]